Market Overview

UPDATE: JP Morgan Cuts PT to $22 on VIVUS Following Q4 Report

Related VVUS
Why VIVUS Might Be A Diamond In The Rough
What's Driving Orexigen Therapeutics Higher?

JP Morgan maintained VIVUS (NASDAQ: VVUS) with an Overweight rating and lowered the price target from $25.00 to $22.00.

JP Morgan commented, "We are maintaining our OW rating on VVUS following yesterday's 4Q report. Updated launch metrics for the obesity drug Qsymia were generally inline with our expectations, and the bottom line is that nothing really changed our overall view. At this stage VVUS is a waiting game. Our prevailing stance is that accessibility (modifying the REMS and improving the reimbursement landscape) and patient/physician experience (through Feb 15, Qsymia had been prescribed to >27K unique pts and the prescriber base is now up to almost 12K providers) will be key to building this market. While we're still optimistic this can and will all come together, we anticipate the jury could remain out until more clear cut evidence is available."

VIVUS closed at $12.41 on Monday.

Latest Ratings for VVUS

DateFirmActionFromTo
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral
Apr 2014Piper JaffrayDowngradesNeutralUnderweight

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (VVUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters